Monash University researchers have found a new way for treating castrate resistant cells in prostate cancer patients.

Associate Dean, Research Centres & Institutes and co-author Professor Gail Risbridger revealed, "The research showed that drugs that activate one of the two estrogen receptors, causes cell death. Most commonly cell death in patients with prostate cancer is achieved by withdrawing androgens which results in castration”.

As a part of the study, the researchers analyzed tissue samples of prostate tumors accumulated from 236 men undergoing prostate cancer surgery. The patients included 37 who took statins over the year prior to their surgery.

It revealed that a net 82 percent men possessed inflammatory cells in their prostate tumors and nearly 33% had marked tumor inflammation.

The findings of the study, conducted by scientists from the Prostate & Breast Cancer Research Program, have appeared in the medical journal PNAS.